Companies › Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GTAEXS617 | – | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Jan 2028 |
| EXS73565 unclear - code-named drug candidate for B-cell malignancies | – | Phase 1 | Relapsed or Refractory B-cell Malignancies | Jun 2028 |
| EXS74539 (REC-4539) | – | Phase 1 | Solid Tumor | Mar 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05985655 | GTAEXS617 | Phase 1 | Head and Neck Squamous Cell Carcinoma (HNSCC) | Oncology | Jan 2028 |
| NCT06980116 | EXS73565 | Phase 1 | Relapsed or Refractory B-cell Malignancies | Oncology | Jun 2028 |
| NCT07517198 | EXS74539 (REC-4539) | Phase 1 | Solid Tumor | Oncology | Mar 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.